Sliskovic D R, Picard J A, Roark W H, Roth B D, Ferguson E, Krause B R, Newton R S, Sekerke C, Shaw M K
Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105.
J Med Chem. 1991 Jan;34(1):367-73. doi: 10.1021/jm00105a057.
A series of substituted quinoline mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and (cholesterol biosynthesis) in vivo. Since previous studies suggested that the 4-(4-fluorophenyl) and 2-(1-methylethyl) substituents afforded optimum potency, attention was focused on variations at position 6 of the quinoline ring. Biological evaluation of a small number of analogues bearing a variety of 6-substituents showed that modification at this position had little effect on potency. Several compounds (8b, 8e, and 11) were identified that showed comparable potency to compactin and mevinolin in both the in vitro and in vivo assays.
制备了一系列取代喹啉甲羟戊酸内酯,并对其在体外和体内(胆固醇生物合成)抑制HMG-CoA还原酶的能力进行了评估。由于先前的研究表明,4-(4-氟苯基)和2-(1-甲基乙基)取代基具有最佳活性,因此注意力集中在喹啉环6位的变化上。对少量带有各种6-取代基的类似物进行的生物学评估表明,该位置的修饰对活性影响很小。鉴定出几种化合物(8b、8e和11),它们在体外和体内试验中均显示出与洛伐他汀和辛伐他汀相当的活性。